tiprankstipranks
Biolidics Ltd. (SG:8YY)
SGX:8YY
Singapore Market

Biolidics Ltd. (8YY) Share Price & Analysis

0 Followers

8YY Stock Chart & Stats

Day’s RangeS$0 - S$0
52-Week Range<S$0.01 - S$0.02
Previous CloseS$0.01
Volume100.00
Average Volume (3M)2.28M
Market Cap
S$6.70M
Enterprise ValueS$6.99M
Total Cash (Recent Filing)S$3.96M
Total Debt (Recent Filing)S$4.25M
Price to Earnings (P/E)
Beta-0.76
Aug 09, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding744,758,836
10 Day Avg. Volume880,980
30 Day Avg. Volume2,279,195
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

3.49%0.00%0.00%96.51%
3.49%
Insiders
0.00% Other Institutional Investors
96.51% Public Companies and
Individual Investors

8YY FAQ

What was Biolidics Ltd.’s price range in the past 12 months?
Biolidics Ltd. lowest share price was <S$0.01 and its highest was S$0.02 in the past 12 months.
    What is Biolidics Ltd.’s market cap?
    Currently, no data Available
    When is Biolidics Ltd.’s upcoming earnings report date?
    Biolidics Ltd.’s upcoming earnings report date is Aug 09, 2024 which is in 19 days.
      How were Biolidics Ltd.’s earnings last quarter?
      Biolidics Ltd. released its earnings results on May 14, 2024. The company reported -S$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -S$0.001.
        Is Biolidics Ltd. overvalued?
        According to Wall Street analysts Biolidics Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Biolidics Ltd. pay dividends?
          Biolidics Ltd. does not currently pay dividends.
          What is Biolidics Ltd.’s EPS estimate?
          Biolidics Ltd.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Biolidics Ltd. have?
          Biolidics Ltd. has 744,758,850 shares outstanding.
            What happened to Biolidics Ltd.’s price movement after its last earnings report?
            Biolidics Ltd. reported an EPS of -S$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Biolidics Ltd.?
              Currently, no hedge funds are holding shares in SG:8YY
              ---

              Biolidics Ltd. Stock Smart Score

              10
              Unlock Smart Score
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Company Description

              Biolidics Ltd.

              Biolidics Ltd is engaged in research, experimental development, marketing, and distribution of biotechnology, life and medical science and electronics related industrial design services and investment holding. Its segments include Cancer; Infectious diseases; Laboratory services; and Corporate segment. It derives major revenue from The infectious diseases segment that involves the identifying and assessing potential collaboration partners, technology, products and services, product development, innovation and improvement and the management of global distributorship network and direct customers in the infectious diseases field. Its operations are spread across Singapore, Japan, China, Europe, United States, Hong Kong, Philippines, Indonesia, and Others.
              ---
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis